• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BioCorRx launches R&D program for anti-addiction naltrexone drug-device combo

July 14, 2016 By Fink Densford

BioCorRxAnti-addiction developer BioCorRx said today it launched a research & development initiative as it seeks FDA approval for its naltrexone implant designed to treat opioid and alcohol addictions.

The implant slowly releases naltrexone, a non-addictive opioid antagonist that can reduce physical cravings and block some of the effects of alcohol and opioids, the Los Angeles-based company said.

“While we continue to observe positive results in our practice, currently the FDA has not given a specific approval for the administration of naltrexone by having it implanted under the skin. Vivitrol, the first FDA approved 30-day injectable form of naltrexone, has led to meaningful market penetration, demonstrating strong demand for this application. Furthermore, with the recent approval of Probuphine by the FDA, implants to treat addiction in general are getting more exposure. Our objective is to expand the addressable market for our treatment targets and seeking FDA approval for our naltrexone implant is a logical next step. To support this endeavor, we anticipate announcing strategic relationships with experienced FDA advisors and consultants in the near term and will provide further details as our strategy unfolds.,” CEO Brady Granier said in a prepared statement.

The initiative is being funded by a previously announced $2.5 million investment from Alpine Creek, BioCorRx said. The company also plans to use the R&D platform to evaluate other compounds to expand its pipeline of addiction treatment services.

Filed Under: Drug-Device Combinations, Research & Development Tagged With: BioCorRx

IN CASE YOU MISSED IT

  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS